Glessner Coleen 4

What Happened

• Coleen Glessner, EVP, Quality & Ethics (and CPL) at Emergent BioSolutions (EBS), had performance stock units (PSUs) for the 2023–2025 performance period certified on Feb 6, 2026 at a 25% payout. That produced 9,615 shares of common stock at $10.92 per share.
• Of the previously reported 38,462 target units, 28,847 units were effectively canceled/disposed (28,847 shares × $10.92 = $315,009). Separately, 2,852 shares were withheld to cover taxes on settlement (2,852 × $10.92 = $31,144). Net shares delivered to Glessner after tax withholding = 9,615 − 2,852 = 6,763 shares (≈ $73,852 at $10.92).

Key Details

• Transaction date: 2026-02-06; Form filed: 2026-02-10 (check official filing for any timeliness flags).
• Prices: $10.92 per share for the reported dispositions/withholding.
• Reported disposition entries:
  • D (Disposition to issuer): 28,847 shares at $10.92 — $315,009 (cancellation of previously reported target units).
  • F (Payment of tax liability / shares withheld): 2,852 shares at $10.92 — $31,144 (tax withholding on settlement).
• Shares owned after the transaction: not provided in the supplied data — see the official Form 4 for post-transaction holdings.
• Footnotes:
  • F1: PSUs were performance-based (cumulative revenue & adjusted EBITDA over 2023–2025). Committee certified payout at 25%, yielding 9,615 shares vs. 38,462 previously reported.
  • F2: 2,852 shares were withheld to pay taxes on vesting/settlement of restricted units.

Context

• This was not an open-market sale or purchase; it was the settlement of performance-based equity with a partial payout and shares withheld for taxes (a common administrative occurrence). The larger “disposition” line reflects cancellation of unearned target units rather than a sale to a third party.
• Purchases by insiders are generally more suggestive of personal bullishness; this filing documents a performance award settlement and tax withholding, not a market trade.